Sawai Group Holdings Co., Ltd.
SWGHF
Other OTC11.52
USD
- -
- -
ISIN
JP3323040000
Return %
Stock
S&P500
1Y
- -
18.86
3Y
28.00
64.57
5Y
-26.76
71.65
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Mitsuo Sawai
- Full Time Employees
- 3,630
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 5-2-30, Miyahara Osaka OS Japan 532-0003
- IPO Date
- Nov 9, 2021
- Website
- sawaigroup.holdings
- Similar Companies
- Business
- Sawai Group Holdings Co., Ltd. operates as a holding company primarily engaged in the pharmaceutical industry, focusing on the research, development, production, and distribution of generic drugs in various therapeutic areas including hypertension, dyslipidemia, and diabetes. Its core subsidiary, Sawai Pharmaceutical Co., Ltd., is a leading Japanese manufacturer of high-quality, affordable generic medications. The company also extends its business into digital health and wellness by providing treatment support applications, health monitoring devices, and IT-based healthcare solutions through subsidiaries such as FrontAct Co., Ltd. It manufactures and markets pharmaceutical products and devices, including the non-invasive neuromodulation device Relivion® for acute-stage migraine treatment, approved in Japan in 2023. The company operates primarily in Japan with aspirations to expand internationally. In recent major developments, Sawai Group Holdings completed the acquisition of FrontAct Co., Ltd. in mid-2025, enhancing its digital health and healthcare technology capabilities. Earlier in 2024, it divested its U.S. business, Sawai America Holdings Inc., to Bora Pharmaceuticals Co., Ltd. for approximately $210 million, focusing more on its core pharmaceutical manufacturing and domestic market strategy. The company has also been active in patent litigation settlements related to its Teriparatide Subcutaneous Injection product and has adjusted its financial guidance subsequently. Additionally, Sawai has increased its dividend payouts in 2025 and conducted share buybacks, reflecting capital management efforts. Sawai Group Holdings continues to develop and market a broad portfolio of over 2,000 product lines with ongoing approvals for new generic drugs in Japan, aligned with its mission to reduce healthcare costs and contribute to sustainable healthcare systems. Founded in 1929 and headquartered in Osaka, Japan, Sawai Group Holdings Co., Ltd. conducts comprehensive pharmaceutical development and manufacturing operations along with medical device and digital healthcare services. Its business segments cover prescription pharmaceuticals, medical devices, digital health solutions, and wellness services, targeting patients, healthcare professionals, and healthcare institutions. The Group aims to support healthier lives through affordable medication and innovative healthcare technologies, reinforcing its status as a key player in the Japanese pharmaceutical market with growing global reach. This profile reflects Sawai Group Holdings’ dual focus on traditional pharmaceutical products and emerging digital health initiatives as it navigates recent structural changes and strategic acquisitions to strengthen its market position and broaden its healthcare impact.